Pharming Shareholders appoint Sijmen de Vries as new CEO

15-Oct-2008 - Netherlands

Pharming Group NV announced the appointment of Dr Sijmen de Vries as Chief Executive Officer (CEO) of Pharming. This decision was taken by the Shareholders at an Extraordinary Meeting (EGM). Dr de Vries will take up his position as of November 3, 2008 as successor to Dr Francis J. Pinto who will retire at the next Annual General Meeting of Shareholders (AGM) of the Company in 2009. Until then, Dr Pinto will stay on as Non-Executive Chairman of the Management Board to ensure a smooth transition.

Sijmen de Vries, MD, MBA, is a 48-year old Dutch national, with extensive senior level experience in both the pharmaceutical and biotechnology industries. He joins Pharming from Swiss-based 4-Antibody where he was CEO. Dr de Vries has also been CEO of Morphochem and prior to this spent many years at Novartis and at SmithKline Beecham Pharmaceuticals where he held senior business and commercial positions. Dr de Vries also holds non-executive directorships in two private life science companies.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances